Kodiak Sciences Stock
Kodiak Sciences Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Victor Perlroth
- Employees
- 141
- Market cap
- $5.4 B
- IPO
- 04/10/2018
- Web
- kodiak.com
Kodiak Sciences Inc. (KOD) is a US-based company in the healthcare/biotechnology sector specializing in the development of therapies for retinal diseases. The focus is on its drug candidate KSI 301, an anti-VEGF antibody biopolymer currently being investigated in Phase IIb/III clinical trials for conditions such as…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Kodiak Sciences stock: price history
1D
-2.7%
1W
-14.1%
1M
+161.7%
6M
+91.0%
YTD
+206.7%
1Y
+474.7%
2Y
+2,758.3%
5Y
+283.0%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~34% stronger price swings than usual
Kodiak Sciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Kodiak Sciences Inc. is a biopharma company focused on the clinical development of therapeutics for various retinal diseases. The primary focus is on the drug candidate KSI-301, which is being investigated for conditions such as wet age-related macular degeneration and diabetic macular edema, and is currently in clinical phases IIb/III. The pipeline also encompasses projects for the treatment of inflammatory processes and dry AMD. The business model concentrates on the research and development of pharmaceutical drugs with the objective of subsequent market launch of medications.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Weak
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Kodiak Sciences
Analyst assessment of Kodiak Sciences
PRICE TARGET LOW
US$61.00
CONSENSUS
US$104.40
MEDIAN
US$112.00
PRICE TARGET HIGH
US$126.00
0
STRONG BUY
14
BUY
4
HOLD
1
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 12/10/2026
Kodiak Sciences stock metrics
P/E
-20.47
P/B
87.9
EV/EBITDA
-25.06
RETURN ON EQUITY
-107.4%
NET MARGIN
0.0%
DEBT/EQUITY
1.57
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.5%
FLOAT SHARES
57,478,947
AVG. DAILY VOLUME (30D)
2,908,242
Insider transactions (SEC)
BAKER BROS. ADVISORS LP
BAKER BROS. ADVISORS LP
BAKER BROS. ADVISORS LP
BAKER BROS. ADVISORS LP
BAKER BROS. ADVISORS LP
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.7%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Kodiak Sciences stock
What does Kodiak Sciences do?
Kodiak Sciences Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Victor Perlroth, the company employs around 141 people.
The IPO was on 04/10/2018; the stock trades on NASDAQ under the ticker KOD.
What do analysts say about Kodiak Sciences stock?
19 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$104.40, ranging from US$61.00 to US$126.00, with a median of US$112.00.
This is an external assessment, not a statement by Market Jury.
When does Kodiak Sciences report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 34% stronger than usual.
Does Kodiak Sciences pay a dividend?
No, Kodiak Sciences currently does not pay a dividend.
Which stocks are comparable to Kodiak Sciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Kodiak Sciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kodiak Sciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.